Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

DCPH - Deciphera Pharmaceuticals Inc

IEX Last Trade
12.94
0.120   0.927%

Share volume: 346,158
Last Updated: Tue 08 Aug 2023 09:59:58 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%
$12.82
0.12
0.94%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
23%
Profitability 22%
Dept financing 6%
Liquidity 74%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
$12.94
P/E Ratio 
0.00
DAY RANGE
N/A - $13.08
EPS 
-$2.29
52 WEEK RANGE
$0.00 - $0.00
52 WEEK CHANGE
$0.00
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
86.476 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$0
AVERAGE 30 VOLUME 
$0
Company detail
CEO: Steven Hoerter
Region: US
Website: https://www.deciphera.com
Employees: 0
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

deciphera was established in 2003 based on a deep scientific understanding of kinase inhibitors and a team dedicated to developing sophisticated approaches to therapeutic targeting of kinases. with business and development operations based in boston, and dedicated research capabilities in close proximity to the university of kansas, deciphera has identified small molecule leads for over 50 kinase targets, and has developed a pipeline of small molecule drug candidates for a range of cancers.

Recent news